Download PDF
Thromb Haemost 2020; 120(01): 184-190
DOI: 10.1055/s-0039-3402055
Editor's Choice
Georg Thieme Verlag KG Stuttgart · New York

Thrombosis and Haemostasis 2019 Editor's Choice Papers

Christian Weber 
1   Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
2   German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Germany
3   Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, the Netherlands
,
Anne Rigby
1   Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
,
Gregory Y. H. Lip 
4   Liverpool Centre for Cardiovascular Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
5   Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
› Author Affiliations
Further Information

Publication History

18 November 2019

18 November 2019

Publication Date:
13 January 2020 (online)

Also available at
    Permissions and Reprints

We would like here to raise a toast to a decade of Editor‘s Choice articles! The first article of this type indeed saw the light in 2010 with a then new collaboration as Editors-in-Chief for Thrombosis & Haemostasis.

Following this good tradition also in the current year, we wish to highlight here hot topic articles of the recent past, which received particular resonance within our reader community, as reflected by their citation, download or Altmetrics score.

 

  • References

  • 1 Paciullo F, Momi S, Gresele P. PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention. Thromb Haemost 2019; 119 (03) 359-367
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 2019; 119 (07) 1084-1093
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost 2019; 119 (09) 1384-1393
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Knowles LM, Kagiri D, Bernard M, Schwarz EC, Eichler H, Pilch J. Macrophage polarization is deregulated in haemophilia. Thromb Haemost 2019; 119 (02) 234-245
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Elaïb Z, Lopez JJ, Coupaye M. , et al. Platelet functions are decreased in obesity and restored after weight loss: evidence for a role of the SERCA3-dependent ADP secretion pathway. Thromb Haemost 2019; 119 (03) 384-396
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Yao X, Chen W, Liu J. , et al. Deep vein thrombosis is modulated by inflammation regulated via sirtuin 1/NF-κB signalling pathway in a rat model. Thromb Haemost 2019; 119 (03) 421-430
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Li X, Wang SW, Feng Q. , et al. Novel murine model of immune thrombocytopaenia through immunized CD41 knockout mice. Thromb Haemost 2019; 119 (03) 377-383
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Semple JW, Kapur R. The ultimate murine model of immune thrombocytopaenia. Thromb Haemost 2019; 119 (03) 353-354
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Guillamat-Prats R, Rami M, Herzig S, Steffens S. Endocannabinoid signalling in atherosclerosis and related metabolic complications. Thromb Haemost 2019; 119 (04) 567-575
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Van Avondt K, Maegdefessel L, Soehnlein O. Therapeutic targeting of neutrophil extracellular traps in atherogenic inflammation. Thromb Haemost 2019; 119 (04) 542-552
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Joppich M, Weber C, Zimmer R. Using context-sensitive text mining to identify miRNAs in different stages of atherosclerosis. Thromb Haemost 2019; 119 (08) 1247-1264
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Natarelli L, Weber C. Next-generation therapeutic concepts for atherosclerosis: focus on cell specificity and noncoding RNAs. Thromb Haemost 2019; 119 (08) 1199-1201
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Gencer S, van der Vorst EPC, Aslani M, Weber C, Döring Y, Duchene J. Atypical chemokine receptors in cardiovascular disease. Thromb Haemost 2019; 119 (04) 534-541
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Yamakawa K, Murao S, Aihara M. Recombinant human soluble thrombomodulin in sepsis-induced coagulopathy: an updated systematic review and meta-analysis. Thromb Haemost 2019; 119 (01) 56-65
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Kang J, Park KW, Palmerini T. , et al. Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost 2019; 119 (01) 149-162
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Yamakawa K, Gando S, Ogura H. , et al; Japanese Association for Acute Medicine (JAAM) Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis Trauma (FORECAST) Study Group. Identifying sepsis populations benefitting from anticoagulant therapy: a prospective cohort study incorporating a restricted cubic spline regression model. Thromb Haemost 2019; 119 (11) 1740-1751
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Kearon C, Gu CS, Julian JA. , et al. Pharmacomechanical catheter-directed thrombolysis in acute femoral-popliteal deep vein thrombosis: analysis from a stratified randomized trial. Thromb Haemost 2019; 119 (04) 633-644
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Bikdeli B, Visvanathan R, Jimenez D, Monreal M, Goldhaber SZ, Bikdeli B. Use of prophylaxis for prevention of venous thromboembolism in patients with isolated foot or ankle surgery: a systematic review and meta-analysis. Thromb Haemost 2019; 19 (10) 1686-1694
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Jung H, Yang PS, Sung JH. , et al. Hypertrophic cardiomyopathy in patients with atrial fibrillation: prevalence and associated stroke risks in a nationwide cohort study. Thromb Haemost 2019; 119 (02) 285-293
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Borer JS, Atar D, Marciniak T, Kim MH, Serebruany V. Atrial fibrillation and stroke in patients with hypertrophic cardiomyopathy: important new insights. Thromb Haemost 2019; 119 (03) 355-357
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Steensig K, Olesen KKW, Thim T. , et al. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the Western Denmark Heart Registry. Thromb Haemost 2018; 118 (12) 2162-2170
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Chao T-F, Liao J-N, Tuan T-C. , et al. Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially ‘low-risk’ patients. Thromb Haemost 2019; 119 (07) 1162-1170
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Chao TF, Lip GYH, Lin YJ. , et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost 2018; 118 (04) 768-777
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Stemberger M, Kallenbach F, Schmit E. , et al. Impact of adopting population pharmacokinetics for tailoring prophylaxis in haemophilia A patients: a historically controlled observational study. Thromb Haemost 2019; 119 (03) 368-376
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, Ramírez-Macías I, Lip GYH, Marín F. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost 2019; 119 (12) 1901-1919
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Zhou D, Ding J, Asmaro K. , et al. Clinical characteristics and neuroimaging findings in internal jugular venous outflow disturbance. Thromb Haemost 2019; 119 (02) 308-318
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Field TS, Weijs B, Curcio A. , et al. Incident atrial fibrillation, dementia and the role of anticoagulation: a population-based cohort study. Thromb Haemost 2019; 119 (06) 981-991
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Hohmann C, Hohnloser SH, Jacob J, Walker J, Baldus S, Pfister R. Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation. Thromb Haemost 2019; 119 (06) 971-980
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Quinn TJ, Lane DA. Anticoagulation for atrial fibrillation in older adults-using Big Data for big questions. Thromb Haemost 2019; 119 (06) 855-857
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Ageno W, Haas S, Weitz JI. , et al; GARFIELD-VTE investigators. Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE Registry. Thromb Haemost 2019; 119 (02) 319-327
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Schellong SM, Goldhaber SZ, Weitz JI. , et al. Isolated distal deep vein thrombosis: perspectives from the GARFIELD-VTE Registry. Thromb Haemost 2019; 19 (10) 1675-1685
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Barco S. What's the matter with distal deep vein thrombosis?. Thromb Haemost 2019; 19 (10) 1547-1549
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Weitz JI, Haas S, Ageno W. , et al. Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design. Thromb Haemost 2016; 116 (06) 1172-1179
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Ageno W, Haas S, Weitz JI. , et al. Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE Registry. Thromb Haemost 2019; 119 (08) 1365-1372
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Duffett L, Kearon C, Rodger M, Carrier M. Treatment of superficial vein thrombosis: a systematic review and meta-analysis. Thromb Haemost 2019; 119 (03) 479-489
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Sugiura-Ogasawara M, Ebara T, Matsuki T. , et al; and the Japan Environment & Children's Study (JECS) Group. Endometriosis and recurrent pregnancy loss as new risk factors for venous thromboembolism during pregnancy and post-partum: the JECS birth cohort. Thromb Haemost 2019; 119 (04) 606-617
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Radin M, Schreiber K, Sciascia S. , et al. Prevalence of antiphospholipid antibodies negativisation in patients with antiphospholipid syndrome: a long-term follow-up multicentre study. Thromb Haemost
    PubMed
  • 38 Grilz E, Posch F, Königsbrügge O. , et al. Association of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with the risk of thromboembolism and mortality in patients with cancer. Thromb Haemost 2018; 118 (11) 1875-1884
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Aharon A, Sabbah AR, Issman L. , et al. Effects of low- and high-dose chemotherapy agents on thrombogenic properties of extracellular vesicles derived from breast cancer cell lines. Thromb Haemost 2018; 118 (03) 480-489
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Kraaijpoel N, Di Nisio M, Mulder FI. , et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study. Thromb Haemost 2018; 118 (08) 1439-1449
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Kraaijpoel N, van Es N, Raskob GE. , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE Study. Thromb Haemost 2018; 118 (07) 1270-1278
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Pelland-Marcotte MC, Pole JD, Kulkarni K. , et al. Thromboembolism incidence and risk factors in children with cancer: a population-based cohort study. Thromb Haemost 2018; 118 (09) 1646-1655
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Campello E, Henderson MW, Noubouossie DF, Simioni P, Key NS. Contact system activation and cancer: new insights in the pathophysiology of cancer-associated thrombosis. Thromb Haemost 2018; 118 (02) 251-265
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Kraaijpoel N, van Es N, Bleker SM. , et al. Clinical impact and course of anticoagulant-related major bleeding in cancer patients. Thromb Haemost 2018; 118 (01) 174-181
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Carmona-Bayonas A, Jimenez-Fonseca P, Garrido M. , et al. Multistate models: accurate and dynamic methods to improve predictions of thrombotic risk in patients with cancer. Thromb Haemost 2019; 119 (11) 1849-1859
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Pelland-Marcotte M-C, Tole S, Pechlivanoglou P, Brandão LR. Effectiveness and safety of primary thromboprophylaxis in children with cancer: a systematic review of the literature and network meta-analysis. Thromb Haemost
    PubMedGoogle Scholar
  • 47 Sumaya W, Geisler T, Kristensen SD, Storey RF. Dual antiplatelet or dual antithrombotic therapy for secondary prevention in high-risk patients with stable coronary artery disease?. Thromb Haemost 2019; 19 (10) 1583-1589
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Pastori D, Eikelboom JW, Anand SS. , et al. Management of patients with asymptomatic and symptomatic carotid artery disease: update on anti-thrombotic therapy. Thromb Haemost 2019; 119 (04) 576-585
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Cohen AT, Agnelli G, Buller HR. , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thromb Haemost 2019; 119 (03) 461-466
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Franchi F, Rollini F, Garcia E. , et al. Effects of edoxaban on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel: results of the EDOX-APT Study. Thromb Haemost 2019; 120 (02) 83-93
    PubMedGoogle Scholar
  • 51 Gorog DA. Understanding the effects of NOAC combined with antiplatelet therapy on clot kinetics. Thromb Haemost
    PubMedGoogle Scholar
  • 52 Hohnloser SH, Basic E, Nabauer M. Changes in oral anticoagulation therapy over one year in 51,000 atrial fibrillation patients at risk for stroke: a practice-derived study. Thromb Haemost 2019; 119 (06) 882-893
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Weitz JI, Chan NC. Long-term management of venous thromboembolism: lessons from EINSTEIN CHOICE and other extension trials. Thromb Haemost 2019; 119 (05) 689-694
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 De Caterina R, Ageno W, Agnelli G. , et al. The non-vitamin K antagonist oral anticoagulants in heart disease: section V-special situations. Thromb Haemost 2019; 119 (01) 14-38
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Pritchett RV, Bem D, Turner GM. , et al. Improving the prescription of oral anticoagulants in atrial fibrillation: a systematic review. Thromb Haemost 2019; 119 (02) 294-307
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Fanikos J, Murwin D, Gruenenfelder F. , et al. Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO Surveillance Program. Thromb Haemost 2019; 120 (02) 83-93
    PubMedGoogle Scholar
  • 57 Fauchier L, Potpara T. Idarucizumab for reversion of anticoagulant effect in daily practice. Thromb Haemost
    PubMedGoogle Scholar
  • 58 Attard C, Ignjatovic V. Primary thromboprophylaxis in children with cancer: a road less travelled. Thromb Haemost 2019 119. (12)
    PubMedGoogle Scholar
  • 59 Agnelli G, Becattini C, Bauersachs R. , et al; Caravaggio Study Investigators. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio Study. Thromb Haemost 2018; 118 (09) 1668-1678
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 O'Brien SH, Li D, Mitchell LG. , et al. PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (ALL)-rationale and design. Thromb Haemost 2019; 119 (05) 844-853
    Article in Thieme ConnectPubMedGoogle Scholar